Conversion study of hepatocellular carcinoma using HAIC combined with lenvatinib and PD-1/L1 immunotherapy under the guidance of BCLC staging
The combination of HAIC with lenvatinib and immunotherapy yielded a high ORR, improved the conversion therapy rate, and prolonged both OS and PFS in patients with uHCC while maintaining a favorable safety profile. BCLC stage was identified as an independent prognostic factor influencing the success of conversion therapy, with patients in stage B deriving significant survival benefits post-conversion.
Authors
- Tongguo Si
- Haipeng Yu (ORCID: https://orcid.org/0000-0002-7240-7526)
- Wei Gao (ORCID: https://orcid.org/0000-0002-6054-382X)
- Xueling Yang (ORCID: https://orcid.org/0000-0001-5440-5351)
- Weihao Zhang (ORCID: https://orcid.org/0000-0002-9301-8538)
- Qiang Zou (ORCID: https://orcid.org/0000-0003-0029-8532)
- Wenge Xing (ORCID: https://orcid.org/0000-0003-3882-2934)
- Xiaohui Zhao
Institutions
- Tianjin Medical University Cancer Institute and Hospital (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-06-02
- DOI
- https://doi.org/10.3389/fimmu.2025.1596864
- Citations
- 1
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 1.32